CAMBRIDGE, Mass., Aug. 08, 2018 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ:MRSN), a clinical-stage
biopharmaceutical company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs) based on its
Dolaflexin® and other proprietary platforms, today announced that Anna Protopapas, President and Chief Executive Officer, will
present a company overview at the Wedbush PacGrow Healthcare Conference in New York, NY, on Wednesday, August 15, 2018 at 1:55 p.m.
ET.
A live webcast of the presentation will be available on the Investors & Media section of Mersana’s website at
www.mersana.com. An archived replay will be available for approximately 60 days following the
presentation.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to
develop highly targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefit to
patients. Mersana’s product candidate XMT-1522 is in Phase 1 clinical trials in patients with advanced tumors expressing
HER2, including breast cancer, non-small-cell-lung-cancer (NSCLC) and gastric cancer patients. The Company’s second product
candidate, XMT-1536, is in Phase 1 clinical trials in patients with tumors expressing NaPi2b, including ovarian cancer, NSCLC and
other cancers. In addition, multiple partners are using Mersana’s platform to advance their ADC pipelines.
Media Contact
Paul Kidwell
paulkidwell@mersana.com
617-680-1088
Investor Contact
Stern Investor Relations, Inc.
Christina Tartaglia
christina@sternir.com
212-362-1200
